The relationship between pharmaceutical expenditure and life expectancy: evidence from 21 OECD countries
- 30 October 2009
- journal article
- research article
- Published by Taylor & Francis in Applied Economics Letters
- Vol. 16 (16) , 1651-1655
Abstract
The purpose of this article is to examine the effect of pharmaceutical expenditures on life expectancy for 21 OECD countries. An unbalanced panel data model is used to investigate the role of socio-economic, lifestyle and demographic factors as well as public and private pharmaceutical expenditures in determining life expectancy for six age–gender strata over the period 1985 to 2002. The empirical results show that pharmaceutical expenditure has a positive, but different effect on life expectancy for females and males with various ages.Keywords
This publication has 9 references indexed in Scilit:
- The Determinants of Life Expectancy: An Analysis of the OECD Health DataSouthern Economic Journal, 2005
- Public and private pharmaceutical spending as determinants of health outcomes in CanadaHealth Economics, 2004
- Sources of U.S. longevity increase, 1960–2001The Quarterly Review of Economics and Finance, 2004
- Is There a Link Between Pharmaceutical Consumption and Improved Health in OECD Countries?*PharmacoEconomics, 2000
- The Effect of Pharmaceutical Utilization and Innovation on Hospitalization and Mortality1996
- Comparing the Performance of Health Care Systems: An Alternative ApproachSouthern Economic Journal, 1994
- A Comparison of International Health Outcomes and Health Care SpendingInternational Journal of Technology Assessment in Health Care, 1994
- Regulation and health: The case of mandatory prescriptions and an extensionManagerial and Decision Economics, 1987
- The Production of Health, an Exploratory StudyThe Journal of Human Resources, 1969